Roy Herbst, MD, PhD: Adjuvant Osimertinib for EGFR-Mutated Non-Small Cell Lung Cancer

Recently, the FDA approved osimertinib (Tagrisso®, AstraZeneca) as the first adjuvant therapy for patients with surgically resected early-stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. In this interview, Roy Herbst, MD, PhD, Chief of Medical Oncology at Yale Cancer Center and lead investigator of the ADAURA trial, on which the approval was based, speaks with i3 Health about the significance of the approval of osimertinib for this patient populati...
Continue reading

Radiotherapy Dose Exposure Linked to Major Adverse Cardiac Events in NSCLC

In patients with locally advanced non-small cell lung cancer (NSCLC) treated with thoracic radiotherapy, a greater left anterior descending (LAD) coronary artery dose exposure was associated with an increased risk of major adverse cardiac events (MACE) and all-cause mortality, particularly in patients with baseline coronary heart disease (CHD), according to results of a cohort study now published in JAMA Oncology. "Development of cardiac adverse events is a well-recognized risk following radioth...
Continue reading

Adjuvant Osimertinib Approved for EGFR-Mutated Non-Small Cell Lung Cancer

The FDA has approved osimertinib (Tagrisso®, AstraZeneca) for patients with surgically resected early-stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations. Previously approved for the first-line treatment of metastatic EGFR-mutated disease, osimertinib is the first adjuvant therapy to be approved for patients with EGFR-mutated NSCLC. The approval was based on the phase 3 ADAURA trial (NCT02511106). "Approximately 30% o...
Continue reading

Atezolizumab for Previously Treated Non-Small Cell Lung Cancer: Julien Mazières, MD, PhD

For patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC), effective treatment options with minimal toxicity remain limited. In this interview with i3 Health, Julien Mazières, MD, PhD, Professor of Respiratory Medicine at Toulouse University Hospital, discusses his collaborative research finding that atezolizumab increases long-term overall survival compared with docetaxel, regardless of histology, subsequent immunotherapy, and programmed death ligand...
Continue reading

New Durvalumab Dosing Schedule Approved for Urothelial Carcinoma and Non-Small Cell Lung Cancer

 The FDA recently approved new doses of durvalumab (Imfinzi®, AstraZeneca) for the treatment of patients with previously treated advanced urothelial carcinoma and unresectable stage III non-small cell lung cancer. "Durvalumab, a selective, high-affinity, engineered human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD80, is approved in the US, Japan, and several other countries for the treatment of patients with unresectable, stage III NSCLC whose disease has not progressed following conc...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.